Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer’s disease to the U.S. FDA completed

BioArctic AB’s partner Eisai announced that Eisai has submitted a supplemental Biologics License Application for monthly lecanemab-irmb intravenous maintenance dosing to the U.S. Food and Drug Administration.